Merck & Co vs Novartis

Merck & Co (MRK), health care, and Novartis (NVS), health care, side by side on market value, valuation, margins, balance sheet and price change. Higher and lower are marked; neither is called better.

Merck & Co is worth $354.4B on the stock market and Novartis $301.5B: Merck & Co is valued at 18% more. Merck & Co trades at 145 times earnings and Novartis at 30.5. Over the past year Merck & Co's share price has moved +49.8% and Novartis's +25.1%.

Key facts

Merck & Co market value
$354.4B
Novartis market value
$301.5B
Merck & Co P/E
145
Novartis P/E
30.5
Merck & Co revenue
$65BFY to 2025-12-31
Novartis revenue
$54.5BFY to 2025-12-31
Superinvestors holding both
8

Market values as of .

Merck & Co vs Novartis: every measure side by side
Measure Merck & Co Novartis
SectorHealth CareHealth Care
Country United States Switzerland
Fiscal year ends2025-12-312025-12-31
Size
Market cap$354.4Bhigher$301.5Blower
Revenue$65Bhigher$54.5Blower
Earnings$18.3Bhigher$14Blower
Employees73,000lower75,267higher
Total assets$136.9Bhigher$110.9Blower
Valuation
P/E145higher30.5lower
P/S5.5lower5.5higher
P/B7.9—
Dividend yield2.33%—
Profitability
Operating margin—32.4%
Balance sheet
Net assets$52.6Bhigher$46.1Blower
Total liabilities$84.2Bhigher$64.4Blower
Total debt$49.3Bhigher$28.7Blower
Cash on hand$14.6Bhigher$11.4Blower
Price change
Today-0.48%lower-0.35%higher
1 year+49.8%higher+25.1%lower

Market value, P/E, P/B, dividend yield and price changes are from live quotes (Yahoo Finance; prices may be delayed 15 minutes or more). Revenue, earnings, operating margin and the balance-sheet figures are from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day. P/S sets today's market value against the latest fiscal year's revenue. “Higher” and “lower” compare the two numbers only; a higher P/E or more debt is not better. Dividend yield and P/B are shown only for companies based in the US. A dash means no figure is on file.

Loading the one-year price chart…

Which superinvestors hold them

From each tracked investor's latest 13F filing. A 13F lists long positions in US-listed shares at a quarter end, filed up to 45 days later.

Percentages are each holding's share of that investor's reported portfolio (under "Both": Merck & Co / Novartis). Who owns MRK · Who owns NVS

Further comparisons

Learn

Questions and answers

Which is bigger, Merck & Co or Novartis?

By market value, Merck & Co is the larger: $354.4B against $301.5B for Novartis. By revenue in its latest fiscal year, Merck & Co is the larger: $65B against $54.5B for Novartis.

Which has the higher P/E ratio?

Merck & Co: 145, against 30.5 for Novartis. A higher P/E means the market pays more for each dollar of the last twelve months' earnings; on its own it does not say which is the better value.

Which has more debt?

Merck & Co: $49.3B, against $28.7B for Novartis. Total debt is borrowings at the end of the latest fiscal year, as each company reported it; it is not set against cash here.

Which superinvestors own both Merck & Co and Novartis?

In their latest 13F filings, Thomas Kahn, Ken Fisher, Jeremy Grantham (co-founder), Charles Brandes (founder), Brandon Haley, Murray Stahl, Dodge & Cox team and Rajiv Jain hold both.

Cite this page

Funkfolio, “Merck & Co vs Novartis”, data as of 17 November 2026. https://funkfolio.com/compare/mrk-vs-nvs

Underlying data: Yahoo Finance quotes; SEC annual reports collected 2026-11-12; 13F filings.